Neuberger Berman Group’s Intellia Therapeutics NTLA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-42,869
| Closed | -$500K | – | 2030 |
|
|
2024
Q4 | $500K | Sell |
42,869
-86,029
| -67% | -$1.34M | ﹤0.01% | 1525 |
|
|
2024
Q3 | $2.65M | Sell |
128,898
-42,464
| -25% | -$979K | ﹤0.01% | 1069 |
|
|
2024
Q2 | $3.84M | Buy |
171,362
+37,575
| +28% | +$895K | ﹤0.01% | 964 |
|
|
2024
Q1 | $3.68M | Sell |
133,787
-1,850
| -1% | -$51.4K | ﹤0.01% | 998 |
|
|
2023
Q4 | $4.14M | Sell |
135,637
-10,784
| -7% | -$310K | ﹤0.01% | 955 |
|
|
2023
Q3 | $4.63M | Buy |
146,421
+7,870
| +6% | +$305K | ﹤0.01% | 900 |
|
|
2023
Q2 | $5.65M | Buy |
138,551
+33,734
| +32% | +$1.37M | 0.01% | 856 |
|
|
2023
Q1 | $3.91M | Sell |
104,817
-3,533
| -3% | -$139K | ﹤0.01% | 927 |
|
|
2022
Q4 | $3.78M | Sell |
108,350
-31,325
| -22% | -$1.49M | ﹤0.01% | 927 |
|
|
2022
Q3 | $7.83M | Buy |
139,675
+9,798
| +8% | +$608K | 0.01% | 786 |
|
|
2022
Q2 | $6.74M | Buy |
129,877
+19,168
| +17% | +$973K | 0.01% | 824 |
|
|
2022
Q1 | $8.06M | Sell |
110,709
-12
| -0% | -$1.02K | 0.01% | 850 |
|
|
2021
Q4 | $13.1M | Buy |
110,721
+4,896
| +5% | +$613K | 0.01% | 780 |
|
|
2021
Q3 | $14.1M | Buy |
105,825
+12,998
| +14% | +$1.97M | 0.01% | 757 |
|
|
2021
Q2 | $15.1M | Sell |
92,827
-19,854
| -18% | -$1.55M | 0.01% | 756 |
|
|
2021
Q1 | $9.06M | Buy |
112,681
+32,429
| +40% | +$2.18M | 0.01% | 838 |
|
|
2020
Q4 | $4.38M | Buy |
80,252
+17,832
| +29% | +$648K | ﹤0.01% | 939 |
|
|
2020
Q3 | $1.25M | Buy |
62,420
+6,385
| +11% | +$133K | ﹤0.01% | 1157 |
|
|
2020
Q2 | $1.18M | Sell |
56,035
-4,777
| -8% | -$81.2K | ﹤0.01% | 1108 |
|
|
2020
Q1 | $744K | Buy |
60,812
+1,883
| +3% | +$25.4K | ﹤0.01% | 1155 |
|
|
2019
Q4 | $864K | Sell |
58,929
-695
| -1% | -$9.67K | ﹤0.01% | 1182 |
|
|
2019
Q3 | $796K | Hold |
59,624
| – | – | ﹤0.01% | 1191 |
|
|
2019
Q2 | $976K | Buy |
59,624
+5,665
| +10% | +$89.1K | ﹤0.01% | 1173 |
|
|
2019
Q1 | $922K | Buy |
53,959
+7,550
| +16% | +$113K | ﹤0.01% | 1131 |
|
|
2018
Q4 | $633K | Sell |
46,409
-26,981
| -37% | -$502K | ﹤0.01% | 1202 |
|
|
2018
Q3 | $2.1M | Buy |
73,390
+8,405
| +13% | +$245K | ﹤0.01% | 1026 |
|
|
2018
Q2 | $1.78M | Sell |
64,985
-1,220
| -2% | -$29.6K | ﹤0.01% | 1087 |
|
|
2018
Q1 | $1.4M | Buy |
66,205
+725
| +1% | +$17.8K | ﹤0.01% | 1092 |
|
|
2017
Q4 | $1.26M | Buy |
65,480
+4,565
| +7% | +$105K | ﹤0.01% | 1125 |
|
|
2017
Q3 | $1.51M | Buy |
60,915
+11,398
| +23% | +$215K | ﹤0.01% | 1049 |
|
|
2017
Q2 | $792K | Buy |
49,517
+6,431
| +15% | +$89.9K | ﹤0.01% | 1206 |
|
|
2017
Q1 | $607K | Sell |
43,086
-2,650
| -6% | -$35.6K | ﹤0.01% | 1259 |
|
|
2016
Q4 | $600K | Sell |
45,736
-32,750
| -42% | -$492K | ﹤0.01% | 1256 |
|
|
2016
Q3 | $1.34M | Buy |
78,486
+1,000
| +1% | +$19.4K | ﹤0.01% | 1043 |
|
|
2016
Q2 | $1.65M | Buy |
+77,486
| New | +$2.06M | ﹤0.01% | 1005 |
|
Other funds holding NTLA
AIM
RP
NAMA
Neuberger Berman Group's NTLA Position: Q1 2025 in Review
Neuberger Berman Group sold out of Intellia Therapeutics (NTLA) in Q1 2025, closing a stake of 42,869 shares — an estimated $500K sold.
Neuberger Berman Group first reported a position in NTLA in Q2 2016 and held it in 35 quarters. The position peaked at $15.1M in Q2 2021. 294 funds tracked by Wall St. Rank hold NTLA as of Q1 2025.
- Neuberger Berman Group reported no remaining Intellia Therapeutics position as of Q1 2025 after selling out during the quarter.
- Neuberger Berman Group sold 42,869 Intellia Therapeutics shares in Q1 2025, an estimated $500K.
- Neuberger Berman Group first reported a position in Intellia Therapeutics in Q2 2016 and held it in 35 quarters.
- Neuberger Berman Group's Intellia Therapeutics position peaked at $15.1M in Q2 2021.
- 294 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2025.
Based on Neuberger Berman Group's 13F filing for Q1 2025, filed 13 May 2025.